Risk factors for the development of Spitz neoplasms

Sarah Benton BA1 | Andrew Roth BS1 | Ayesha U. Khan MBA1 | Jeffrey Zhao BA1 | Daniel Kim BS1 | Elsy V. Compres BA1 | Annette M. Wagner MD2 | Lacey L. Kruse MD2 | Bin Zhang MS1 | Pedram Gerami MD1,3

1Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
2Division of Dermatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois, USA
3Robert H. Lurie Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

Abstract

Background/Objectives: The principal environmental risk factor for conventional nevi and melanomas is ultraviolet exposure. However, little is known about genetic or environmental risk factors for developing Spitz tumors. This study investigates risk factors associated with Spitz neoplasms.

Methods: Patients with Spitz tumors seen at Northwestern Memorial Hospital and Lurie Children’s Hospital were surveyed with a 16-item questionnaire about environmental and inherited factors. Spitz tumor patients were compared to a pediatric control cohort from a similar clinical setting. This was supplemented with a meta-analysis of genetic and environmental causes of Spitz neoplasms.

Results: One hundred and six Spitz and 58 control surveys were obtained and no statistically significant differences in genetic or environmental risk factors were found between Spitz and control groups.

Conclusion: Our data and meta-analysis suggest that typical risk factors associated with melanoma are not significantly associated with Spitz tumors. Identification of relevant genetic or environmental risk factors will likely require larger and population-based studies.

Keywords: melanocytic neoplasms, meta-analysis, risk factors, Spitz, survey

1 | INTRODUCTION

It is well recognized that Spitz neoplasms, though featuring histologic similarities to conventional melanoma cytologic atypia, confluent and expansile nesting, pagetoid spread, and mitotic activity, have distinct clinical and genomic characteristics compared to conventional nevi and melanomas, and the vast majority have indolent clinical behavior.1 While most conventional nevi and melanomas are driven by UV-induced point mutations in genes such as BRAF or NRAS, many Spitz neoplasms are the result of chromosomal structural rearrangements in genes such as ALK, ROS1, NTRK1/3, BRAF, RET, and MAP3K8 among others, or harbor HRAS mutations, and these variants underlie the most recent WHO definition of Spitz neoplasms.2

Overall, there are few studies investigating epidemiologic risk factors associated with the development of spitzoid neoplasms, hence risk factors for these tumors remain poorly understood, limiting clinical identification of patients more likely to develop spitzoid neoplasms. We constructed a patient survey focused on demographics, environmental exposures, medical history, and family history to investigate risk factors for Spitz neoplasms and performed a meta-analysis of relevant literature.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2022 The Authors. Pediatric Dermatology published by Wiley Periodicals LLC.
2 | MATERIALS AND METHODS

Institutional Review Board approval was obtained through Lurie Children's Hospital (2019–2027) and Northwestern University (STU1127). We queried medical records between 01/01/2006 and 03/05/2020 to identify patients with biopsy-proven Spitz tumors, including Spitz nevi (SN), atypical Spitz tumors (AST), and Spitz melanomas (SM). Cases diagnosed as atypical or borderline melanocytic tumors with some spitzoid features were excluded.

We developed a questionnaire to identify environmental and inherited factors potentially related to Spitz neoplasm development (Figure S1), which was completed in clinic via REDCap or paper survey or sent electronically via REDCap. Control surveys (n = 58) were obtained from pediatric patients seen in general pediatric dermatology clinic with no history of Spitz neoplasm. All Spitz patients approached were willing to participate in the survey. For controls, patients were screened from general pediatric dermatology clinic to find age-matched controls. Out of 71 control patients approached to complete the survey, 58 (81.7%) agreed and completed the survey.

We completed a literature review of environmental and genetic risk factors related to Spitz neoplasms. We completed a PubMed search using the term “Spitz” along with keywords relating to our survey questions, for example, “race,” “ethnicity,” and “Fitzpatrick” in addition to “epidemiology,” “risk factors,” and “review.”

Statistical comparisons were performed with RStudio v1.2.5001 (RStudio) and IBM SPSS Statistics Version 27.0 (IBM Corp). Fisher’s exact and chi-square tests compared categorical variables. Student’s t-test was used to compare mean values. Statistical significance was set at p < .003, adjusted with the Bonferroni correction for 16 hypotheses.

3 | RESULTS

We obtained 106 completed Spitz neoplasm patient surveys and 58 completed control patient surveys (Tables 1 and 2), with an average age of 8 years at diagnosis, similar gender distribution, and with >50% of respondents in both groups being Fitzpatrick types I to III. The majority of respondents were Caucasian, with similar proportion of European ethnicity (Tables 1 and 2).

| TABLE 1 | Demographic information for survey and control patients |
|-----------------|-----------------|-----------------|
|                | Control n = 58  | Spitz n = 106   |
| Sex            |                 |                 |
| Male           | 33 (56.9%)      | 50 (47.2%)      |
| Female         | 25 (43.1%)      | 56 (52.8%)      |
| Age at diagnosis (years) |             |                 |
| Mean           | 8.26            | 8.31            |
| Range          | 1–18            | 1–26            |

Three survey questions addressed UV exposure in subjects. Spitz respondents reported a higher number of sunburns, with more reporting six or more sunburns compared to control patients (13.2% vs. 3.4%, p = .095). All participants denied tanning bed use. Patients reported a similar amount of time outside during peak times in the year with most respondents spending less than five hours outdoors daily. There was no difference between groups in response to a variety of other exposures, including smoking exposure, poor air quality, and pesticide use (Table 2).

Medical history was not significantly different in Spitz and control groups; five Spitz patients reported cancer histories (of melanoma, leukemia, osteosarcoma, and neuroblastoma (p = .16). History of immunosuppression including radiation therapy, chemotherapy, stem cell transplant, organ transplant, and history of CT imaging demonstrated no difference between groups.

Sixty-one (57.5%) Spitz respondents and 32 (55.2%) control respondents reported a family history (1st or 2nd degree) of either melanoma, non-melanoma skin cancer, lung, ovarian, breast, pancreatic, or thyroid cancer, including 26.4% of Spitz patients and 32.8% of control patients (p = .47) with a family history of melanoma. No association was found with family history of dysplastic nevus syndrome (DNS) (p = 1.00).

4 | DISCUSSION

Chimeric fusion proteins and truncations have been identified as the primary oncogenic drivers in the majority of Spitz neoplasms; changes such as translocations, inversions, duplications, deletions, and complex rearrangements are distinct from the UV-induced mutations common among conventional melanoma. Likewise, risk factors for developing Spitz neoplasms are expected to be distinct. Our study found no reproducible genetic or environmental risk factors for Spitz neoplasms, which is consistent with the literature.

The predominance of Spitz neoplasms in younger patients is consistent with a mechanism of occurrence distinct from UV mutagenesis, which tends to accumulate with age. The literature suggests that 20% of Spitz neoplasms occur before age 10 and up to 75% occur before age 20.5–13 Six retrospective reviews report at least 50% of patients as younger than 20 years old.5,7,8,11,13,14 However, many of these retrospective reviews only report on patients younger than 18–20, or 30-years old. SN do occur in patients of all ages, with some studies documenting their occurrence in skin of older patients.15

Patients younger than 10 years old have a higher prevalence of SN, while AST and SM are more commonly found in patients over 10 years old.16–18 The age difference in SN versus SM was statistically significant in one study.18 While the driver mutations for most Spitz neoplasms are not UV-related, UV mutagenesis may be involved in the progression of SN to AST and SM. TERT promoter mutations, associated with SM, are thought to be UV-induced.19
### TABLE 2  Demographic, exposure, medical history, and family history survey results of Spitz and control patients

| Demographics | Control n=58 | Spitz n=106 | p-value (significance at p<.003) |
|--------------|--------------|-------------|----------------------------------|
| **Race**     |              |             |                                  |
| Caucasian    | 44 (75.8%)   | 88 (83.0%)  | .113                             |
| Caucasian + Black/African American | 1 (1.7%) | 2 (1.9%) |
| Caucasian + Hispanic/Latin | 2 (3.4%) | 2 (1.9%) |
| Caucasian + Asian | 1 (1.7%) | 0 (0.0%) |
| Caucasian + American Indian | 1 (1.7%) | 0 (0.0%) |
| Black/African American | 8 (13.8%) | 5 (4.7%) |
| Hispanic/Latin | 1 (1.7%) | 3 (2.8%) |
| **Ethnicity** |              |             |                                  |
| European     | 33 (56.9%)   | 46 (43.4%)  | .87                              |
| European + Indian | 0 (0.0%) | 1 (0.9%) |
| European + Middle Eastern | 0 (0.0%) | 2 (1.9%) |
| European + African | 0 (0.0%) | 7 (6.6%) |
| European + North American | 0 (0.0%) | 1 (0.9%) |
| European + N American + S American | 0 (0.0%) | 1 (0.9%) |
| European + N American + C American | 1 (1.7%) | 0 (0.0%) |
| European + South American | 0 (0.0%) | 2 (1.9%) |
| European + Central American | 2 (3.4%) | 0 (0.0%) |
| European + Southeast Asian | 1 (1.7%) | 3 (2.8%) |
| Indian       | 0 (0.0%)     | 1 (0.9%)    |                                  |
| Pacific Islands | 0 (0.0%) | 3 (2.8%) |
| Other        | 0 (0.0%)     | 2 (1.9%)    |                                  |
| Middle Eastern | 1 (1.7%) | 0 (0.0%) |
| African      | 15 (25.9%)   | 34 (32.1%)  |                                  |
| North American | 1 (1.7%) | 1 (0.9%) |
| South American | 4 (6.9%) | 0 (0.0%) |
| Central American | 0 (0.0%) | 0 (0.0%) |
| **Fitzpatrick Score** |              |             | .94                              |
| 1            | 8 (13.8%)    | 12 (11.3%)  |                                  |
| 2            | 20 (34.5%)   | 35 (33.0%)  |                                  |
| 3            | 14 (24.1%)   | 32 (30.2%)  |                                  |
| 4            | 11 (19.0%)   | 19 (17.9%)  |                                  |
| 5            | 5 (8.6%)     | 7 (6.6%)    |                                  |
| 6            | 0 (0.0%)     | 1 (0.9%)    |                                  |
| **Year Residence Built** |              |             | .64                              |
| >2000        | 12 (20.7%)   | 29 (27.4%)  |                                  |
| 1980-2000    | 15 (25.9%)   | 25 (23.6%)  |                                  |
| 1960-1979    | 12 (20.7%)   | 16 (15.1%)  |                                  |
| 1940-1959    | 7 (12.1%)    | 15 (14.2%)  |                                  |
| 1920-1939    | 5 (8.6%)     | 3 (2.8%)    |                                  |
| 1900-1919    | 1 (1.7%)     | 7 (6.6%)    |                                  |
| <1900        | 5 (8.6%)     | 6 (5.7%)    |                                  |
| N/A          |             |             |                                  |
| **Number of Sunburns** |              |             | .095                             |
| 0-3          | 51 (87.9%)   | 86 (81.1%)  |                                  |
| 3-6          | 5 (8.6%)     | 6 (5.7%)    |                                  |
| 6-10         | 2 (3.4%)     | 14 (13.2%)  |                                  |
| **Tanning Bed Use** |              |             |                                  |
| Yes          | 0 (0.0%)     | 0 (0.0%)    |                                  |
| No           | 58 (100.0%)  | 106 (100.0%)|                                  |

(Continues)
Additionally, since distinction of benign Spitz from melanoma is generally a greater challenge in adults, pathologists may be more likely to use Spitz tumor in adults and SN in children. The data and literature suggest a slight predominance of spitzoid proliferation in females, with a ratio close to 1.4:1; however, this has been reported as high as 3:1, particularly after age 10–15 years.6,7,10,12,18,20-24

### Table 2 (Continued)

|                                | Control n=58 | Spitz n=106 | p-value (significance at p<.003) |
|--------------------------------|--------------|-------------|----------------------------------|
| **Outdoor Time (hrs/day)**     |              |             |                                  |
| <5                            | 21 (36.2%)   | 13 (12.3%)  | .017                             |
| ≥5                            | 0 (0.0%)     | 31 (29.2%)  |                                  |
| N/A                           |              |             |                                  |
| **Smoking Exposure**           |              |             |                                  |
| No                            | 51 (87.9%)   | 90 (84.9%)  | .81                              |
| Yes                           | 7 (12.1%)    | 15 (14.2%)  |                                  |
| N/A                           | 0 (0.0%)     | 1 (0.9%)    |                                  |
| **Poor Air Quality**          |              |             |                                  |
| No                            | 52 (89.7%)   | 93 (87.7%)  | 1.00                             |
| Yes                           | 6 (10.3%)    | 12 (11.3%)  |                                  |
| N/A                           | 0 (0.0%)     | 1 (0.9%)    |                                  |
| **Pesticide Exposure (Yes/No)** |            |             |                                  |
| No                            | 46 (79.3%)   | 75 (70.8%)  | .44                              |
| Yes                           | 12 (20.7%)   | 28 (26.4%)  |                                  |
| N/A                           | 0 (0.0%)     | 3 (2.8%)    |                                  |
| **Immunosuppression†**        |              |             |                                  |
| Yes                           | 2 (3.4%)     | 8 (7.5%)    | .33                              |
| No                            | 56 (96.6%)   | 95 (89.6%)  |                                  |
| N/A                           | 0 (0.0%)     | 3 (2.8%)    |                                  |
| **Imaging**                   |              |             |                                  |
| None                          | 50 (86.2%)   | 94 (88.7%)  | .214                             |
| CT                            | 8 (13.8%)    | 12 (11.3%)  |                                  |

**Medical History**

|                                |              |             |                                  |
| **Personal History of Cancer** |              |             |                                  |
| No                            | 58 (100%)    | 98 (92.5%)  | .16                              |
| Yes                           | 0 (0.0%)     | 5 (4.7%)    |                                  |
| N/A                           | 0 (0.0%)     | 3 (2.8%)    |                                  |
| **Personal History Cancer Type** |            |             | .88                              |
| None                          | 58 (100%)    | 98 (92.5%)  |                                  |
| Melanoma                      | 0 (0.0%)     | 1 (0.9%)    |                                  |
| Leukemia                      | 0 (0.0%)     | 2 (1.9%)    |                                  |
| Osteosarcoma                  | 0 (0.0%)     | 1 (0.9%)    |                                  |
| Neuroblastoma                 | 0 (0.0%)     | 1 (0.9%)    |                                  |
| N/A                           | 0 (0.0%)     | 3 (2.8%)    |                                  |

**Family History**

|                                |              |             |                                  |
| **Family History of Cancer**  |              |             |                                  |
| No                            | 26 (44.8%)   | 40 (37.7%)  | .61                              |
| Yes                           | 32 (55.2%)   | 61 (57.5%)  |                                  |
| N/A                           | 0 (0.0%)     | 5 (4.7%)    |                                  |
| **Family History of DNS§**    |              |             | 1.00                             |
| Yes                           | 3 (5.2%)     | 2 (1.9%)    |                                  |
| No                            | 55 (94.8%)   | 47 (44.3%)  |                                  |
| N/A                           | 0 (0.0%)     | 57 (98.3%)  |                                  |
| **Family History of Melanoma**|              |             | .47                              |
| No                            | 39 (67.2%)   | 77 (72.6%)  |                                  |
| Yes                           | 19 (32.8%)   | 28 (26.4%)  |                                  |
| N/A                           | 0 (0.0%)     | 1 (0.9%)    |                                  |

*Radiation therapy, chemotherapy, stem cell transplant, or organ transplant.
§Dysplastic nevus syndrome.
Races reported by Spitz patients in the survey included Caucasian, Hispanic/Latin, Asian, Caucasian and Black, Caucasian and Hispanic/Latin, and Caucasian and Asian; and ethnicities included African, Asian, Middle Eastern, North and South American, Australian, and European, with no significant difference compared to the control group. Fitzpatrick score was assessed by predisposition to burn or tan, and 74.5% of Spitz patients surveyed reported Type I-III. Meta-analysis suggests Spitz neoplasms most commonly occur in Caucasians; however, Spitz lesions have traditionally been studied in majority Caucasian cohorts and are thought to be underdiagnosed in Black patients. Some studies have focused on characterizing Spitz lesions in Hispanic and Black patients. Incident of SN in the predominantly Caucasian countries of the United States, Australia, and the United Kingdom has been reported as 7, 1.66, and 1.4 per 100,000 persons per year and as <1 in the predominantly Asian country Korea. Greek and Korean studies found a majority of SN patients to be Fitzpatrick Type III or greater. Overall the currently available data suggests Spitz neoplasms are likely more common in Caucasians, but the subject has not been sufficiently studied to form a definitive conclusion on this matter.

4.1 | Exposures

No environmental exposures in the survey yielded a correlation with Spitz neoplasm development, including age of residence, smoking exposure, air quality, pesticide use, sunburns, time spent outdoors, CT imaging, and immunosuppression via chemotherapy, radiation therapy, or transplant. Age of residence, smoking exposure, air quality, pesticide use, and immunosuppression have not been widely studied in the literature. Two studies have investigated possible association of sunburns and Spitz development; however, our study yielded no statistical difference. One study found no patients with tanning bed use, as was the case for our cohort. The lack of a statistically significant association of Spitz tumors with UV exposure is consistent with the vast majority of Spitz neoplasms resulting from larger structural chromosomal rearrangements rather than somatic DNA mutations.

4.2 | Medical history

Patients reported a personal cancer history in 4.7% of the Spitz cohort and 0.0% of the control cohort; however, this difference was not statistically significant (p=.16). Meta-analysis revealed no studies in which personal cancer history was associated with Spitz neoplasm development.

4.3 | Family history

Our data found no significant difference between control and Spitz patients regarding family cancer or melanoma history. A case series of six AST and SM patients found 50% had a family history of non-melanoma skin cancer, and a review found family melanoma history to be associated with AST. However, most studies demonstrate no association of family skin cancer history with Spitz neoplasms. Our study as well as most other investigators report no association of Spitz neoplasms with family history of DNS. Both the Spitz and control survey groups reported a considerably higher rate of melanoma family history (26.4% and 32.8%) than what is to be expected in the general public; one meta-analysis showed 3.1% of control population patients to report a family history of melanoma. We attribute this to the fact that patients with a family history of melanoma are more likely to attend a dermatology clinic.

Our survey and meta-analysis show no reproducible genetic or environmental risk factors for Spitz neoplasms, which are largely caused by structural rearrangements of chromosomes resulting in chimeric fusion proteins with constitutively activated tyrosine kinases. No significant differences were found in race, UV exposure, environmental hazards, or family history of DNS or melanoma between Spitz and control groups after Bonferroni correction for multiple hypothesis testing. If there is an environmental exposure related to Spitz neoplasm development, it is not likely a powerful connection and more cases are required to support it.

Limitations included small overall sample size, self-reported responses (especially relating to family medical history), and recall bias, which may have obscured possible associations with Spitz neoplasm development. A larger study may be needed to more definitively exclude some low-level associations that can only be identified in large multicenter studies. Additionally, controls were obtained from pediatric dermatology clinic, a population that includes a greater proportion of patients with personal and family history of skin conditions, including melanoma and other genetically linked disorders.

ACKNOWLEDGEMENT

Authors Benton and Roth contributed equally to this article. This work was supported by the IDP Foundation.

CONFLICT OF INTEREST

Dr. Gerami has served as a consultant for DermTech Inc. and Castle Biosciences and has received honoraria for this. All other authors report no relevant conflicts of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Lacey L. Kruse https://orcid.org/0000-0003-1410-2457
Pedram Gerami https://orcid.org/0000-0002-6194-1037

REFERENCES

1. Busam KJ, Gerami P, Scolyer RA. Pathology of Melanocytic Tumors. 1st ed. Elsevier; 2019.
2. Elder D, Barnhill R, Bastian B, Cook M, de la Fouchardiere A, Gerami P. Melanocytic Tumour Classification and the Pathway Concept of
Melanoma Pathogenesis. WHO Classification of Skin Tumours. 4th ed IARC. 2018:66-71.

3. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251-263.

4. Quan VL, Panah E, Zhang B, Shi K, Mohan LS, Gerami P. The role of gene fusions in melanocytic neoplasms. J Cutan Pathol. 2019;46(11):878-887.

5. Byrne M, Regan PJ, Kelly JL, Hussey AE. Analysis of features associated with equivocal diagnosis and diagnostic discordance of Spitz naevi over an 18-year period. Eur J Dermatol. 2015;25(2):162-168.

6. Paniago-Pereira C, Maize JC, Ackerman AB. Nevus of large spindle and/or epithelioid cells (Spitz’s nevus). Arch Dermatol. 1978;114(12):1811-1823.

7. Dal Pozzo V, Benelli C, Restano L, Gianotti R, Cesana BM. Clinical review of 247 cases of Spitz naevus (epithelioid cell and/or spindle cell nevus). Dermatol. 1997;194(1):20-25.

8. Herreid PA, Shapiro PE. Age distribution of Spitz naevus vs malignant naevus. Arch Dermatol. 1994;130(3):352-353.

9. Soura E, Dimitrakopoulou A, Christofidou E, Katoulis A, Antoniou C, Stratigos A. Patients with Spitz naevi in the Greek population: epidemiologic, clinical and histopathological characteristics. J Eur Acad Dermatol Venereol. 2018;32(7):1128-1137.

10. Berlingeri-Ramos AC, Morales-Burgos A, Sanchez JL, Nogales EM. Spitz naevus in a Hispanic population: a clinicopathological study of 130 cases. Am J Dermatopathol. 2010;32(3):267-275.

11. Kim YC, Do JE, Bang D, et al. Spitz naevus is rare in Korea. Clin Exp Dermatol. 2010;35(2):135-139.

12. Cesinaro AM, Foroni M, Sighinolfi P, Migaldi M, Trentini GP. Spitz naevus is relatively frequent in adults: a clinico-pathologic study of 247 cases related to patient’s age. Am J Dermatopathol. 2005;27(6):469-475.

13. Weedon D, Little JH. Spindle and epithelioid cell nevi in children and adults. A review of 211 cases of the Spitz naevus. Cancer. 1977;40(1):217-225.

14. Dika E, Ravaloli GM, Fanti PA, Neri I, Patrizi A. Spitz nevi and other Spitzoid neoplasms in children: overview of incidence data and diagnostic criteria. Pediatr Dermatol. 2017;34(1):25-32.

15. Horst BA, Fang Y, Silvers DN, Busam KJ. Chromosomal aberrations by 4-color fluorescence in situ hybridization not detected in Spitz naevi of older individuals. Arch Dermatol. 2012;148(10):1152-1156.

16. Luo S, Sepehr A, Tsao H. Spitz naevi and other Spitzoid lesions part I. Background and diagnoses. J Am Acad Dermatol. 2011;65(6):1073-1084.

17. Soura E, Plaka M, Stefanaki C, et al. Characteristics of Spitz naevi, Atypical Spitz naevi and Melanomas in patients younger than 20 years. J Eur Acad Dermatol Venereol. 2017;31(8):e384-e385.

18. Lott JP, Wiltiwsuannakul J, Lee JJ, et al. Clinical characteristics associated with Spitz naevi and Spitzoid malignant melanomas: the Yale University Spitzoid Neoplasm Repository experience. 1991 to 2008. J Am Acad Dermatol. 2014;71(6):1077-1082.

19. Lee S, Barnhill RL, Dummer R, et al. TERT promoter mutations are predictive of aggressive clinical behavior in patients with Spitzoid melanocytic neoplasms. Sci Rep. 2015;5(1):11200.

20. Scalvenzi M, Costa C, De Fata SG, Cappello M, Villani A. Clinical and dermoscopic features of Spitz naevus by sex, age and anatomical site: a study of 913 Spitz naevi. Br J Dermatol. 2018;179(3):769-770.

21. Dika E, Neri I, Fanti PA, Barisani A, Ravaloli GM, Patrizi A. Spitz naevi: diverse clinical, dermoscopic and histopathological features in childhood. J Dtsch Dermatol Ges. 2017;15(1):70-75.

22. McCarthy SW, Crotty KA, Palmer AA, Ng AB, McCarthy WH, Shaw HM. Cutaneous malignant melanoma in teenagers. Histopathology. 1994;24(5):453-461.

23. Requena C, Requena L, Kutzner H, Sanchez YE. Spitz nevus: a clinicopathological study of 349 cases. Am J Dermatopathol. 2009;31(2):107-116.

24. Hill SJ, Delman KA. Pediatric melanomas and the atypical spitzoid melanocytic neoplasms. Am J Surg. 2012;203(6):761-767.

25. Tom WL, Hsu JW, Eichenfield LF, Friedlander SF. Pediatric “STUMP” lesions: evaluation and management of difficult atypical Spitzoid lesions in children. J Am Acad Dermatol. 2011;64(3):559-572.

26. Karram S, Novy M, Saroufim M, et al. Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure. Am J Dermatopathol. 2013;35(4):412-418.

27. Afanasiev OK, Tu JH, Chu DH, Swetter SM. Characteristics of melanoma in white and nonwhite children, adolescents, and young adults: Analysis of a pediatric melanoma institutional registry, 1995-2018. Pediatr Dermatol. 2019;36(4):444-454.

28. Panasiti V, Barone M, Coppola R, et al. Expression of estrogen receptors in spitz and reed nevi. Ital J Dermatol Venerol. 2019;156(3):378-383.

29. Carr EM, Heilman E, Prose NS. Spitz nevi in black children. J Am Acad Dermatol. 1990;23(5 Pt 1):842-845.

30. Casso EM, Grin-Jorgensen CM, Grant-Kels JM. Spitz nevi. J Am Acad Dermatol. 1992;27(6 Pt 1):901-913.

31. Bovenmyer DA. Spitz’s nevus in a black child. Cutis. 1981;28(2):186-188, 200, 209.

32. Peris K, Ferrari A, Argenziano G, Soyer HP, Chimenti S. Dermoscopic classification of Spitz/Reed nevi. Clin Dermatol. 2002;20(3):259-262.

33. Ko CB, Walton S, Wyatt EH, Bury HP. Spitz nevus. Int J Dermatol. 1993;32(5):354-357.

34. Ford D, Bliss JM, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with a family history of the disease. Int J Cancer. 1995;62(4):377-381.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

_How to cite this article:_ Benton S, Roth A, Khan AU, et al. Risk factors for the development of Spitz neoplasms. Pediatr Dermatol. 2022;39:220–225. doi:10.1111/pde.14957